More than just methylisothiazolinone: Retrospective analysis of patients with isothiazolinone allergy in North America, 2017-2020
Margo J Reeder,Donglin Zhang,Srikanth R Aravamuthan,Erin M Warshaw,Joel G DeKoven,Jonathan I Silverberg,Brandon L Adler,Amber R Atwater,James S Taylor,Marie-Claude Houle,Donald V Belsito,Jiade Yu,Nina Botto,Christen M Mowad,Cory A Dunnick,Vincent A DeLeo,Melanie D Pratt
DOI: https://doi.org/10.1016/j.jaad.2023.10.032
Abstract:Background: Isothiazolinones are a common cause of allergic contact dermatitis. Objective: To examine the prevalence of positive patch test reactions to isothiazolinones from 2017-2020 and characterize isothiazolinone-allergic (Is+) patients compared with isothiazolinone nonallergic (Is-) patients. Methods: Retrospective cross-sectional analysis of 9028 patients patch tested to methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) 0.02% aqueous, MI 0.2% aqueous, benzisothiazolinone (BIT) 0.1% petrolatum, and/or octylisothiazolinone (OIT) 0.025% petrolatum. Prevalence, reaction strength, concurrent reactions, clinical relevance, and source of allergens were tabulated. Results: In total, 21.9% (1976/9028) of patients had a positive reaction to 1 or more isothiazolinones. Positivity to MI was 14.4% (1296/9012), MCI/MI was 10.0% (903/9017), BIT was 8.6% (777/9018), and OIT was 05% (49/9028). Compared with Is-, Is+ patients were more likely to have occupational skin disease (16.5% vs 10.3%, P <.001), primary hand dermatitis (30.2% vs 19.7%, P <.001), and be >40 years (73.1% vs 61.9%, P <.001). Positive patch test reactions to >1 isothiazolinone occurred in 44.1% (871/1976) of Is+ patients. Testing solely to MCI/MI would miss 47.3% (611/1292) of MI and 60.1% (466/776) of BIT allergic reactions. Limitations: Retrospective cross-sectional study design and lack of follow-up data. Conclusion: Sensitization to isothiazolinones is high and concurrent sensitization to multiple isothiazolinone allergens is common.